Pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Grifols has the lowest figure of the 50 pharmaceutical companies ranked by P/S ratio, at 0.7, followed by Viatris (1.7) and GSK (2.2). Figures as of 18 Nov 2026, 19:33 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- Lowest
- Grifols0.7
- Median
- 6.9
- Combined market value
- TRY 255.14T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | GrifolsGRFS · Health Care | 0.7 | TRY 289B | TRY 424.65 | 2.42% down | 1% up | ||
| 2 | ViatrisVTRS · Health Care | 1.7 | TRY 1.19T | TRY 1,038.01 | 0.66% up | 96% up | ||
| 3 | GSKGSK · Health Care | 2.2 | TRY 4.91T | TRY 2,450.94 | 1.29% down | 6% up | ||
| 4 | SanofiSNY · Health Care | 2.3 | TRY 5.71T | TRY 2,379.84 | 0.70% down | 4% down | ||
| 5 | Takeda PharmaceuticalTAK · Health Care | 2.4 | TRY 3.43T | TRY 1,073.06 | 1.66% down | 54% up | ||
| 6 | Amneal PharmaceuticalsAMRX · Health Care | 2.5 | TRY 383.2B | TRY 1,099.79 | 3.27% up | 83% up | ||
| 7 | Bristol-Myers SquibbBMY · Health Care | 2.5 | TRY 6.14T | TRY 3,005.37 | 2.85% down | 34% up | ||
| 8 | PfizerPFE · Health Care | 2.6 | TRY 8.06T | TRY 1,413.94 | 1.51% down | 14% up | ||
| 9 | Elanco Animal HealthELAN · Health Care | 2.8 | TRY 676.7B | TRY 1,353.93 | 3.87% up | 20% up | ||
| 10 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.8 | TRY 2.48T | TRY 2,124.44 | 1.15% down | 74% up | ||
| 11 | PTC TherapeuticsPTCT · Health Care | 2.9 | TRY 252.8B | TRY 3,025.54 | 0.60% down | 20% down | ||
| 12 | Legend BiotechLEGN · Health Care | 3.0 | TRY 158.1B | TRY 814.88 | 0.31% up | 42% down | ||
| 13 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | TRY 629.9B | TRY 755.63 | 1.32% up | 5% up | ||
| 14 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | TRY 595.1B | TRY 3,072.44 | 4.14% up | 11% up | ||
| 15 | ZoetisZTS · Health Care | 3.7 | TRY 1.75T | TRY 4,305.27 | 2.27% up | 29% down | ||
| 16 | Jazz PharmaceuticalsJAZZ · Health Care | 3.7 | TRY 795.5B | TRY 12,392.63 | 2.10% up | 37% up | ||
| 17 | Novo NordiskNVO · Health Care | 3.8 | TRY 8.76T | TRY 1,986.52 | 3.21% down | 17% down | ||
| 18 | Abbott LaboratoriesABT · Health Care | 4.1 | TRY 9.13T | TRY 5,269.99 | 0.19% down | 17% down | ||
| 19 | AstraZenecaAZN · Health Care | 4.7 | TRY 13.96T | TRY 9,002.00 | 2.06% down | 2% up | ||
| 20 | Ionis PharmaceuticalsIONS · Health Care | 4.9 | TRY 232.1B | TRY 1,393.77 | 2.52% up | 64% down | ||
| 21 | Merck & CoMRK · Health Care | 5.2 | TRY 17.07T | TRY 6,924.21 | 4.22% down | 51% up | ||
| 22 | AlkermesALKS · Health Care | 5.3 | TRY 393B | TRY 2,338.75 | 2.05% up | 58% up | ||
| 23 | NovartisNVS · Health Care | 5.4 | TRY 14.77T | TRY 7,820.02 | 2.55% down | 25% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | 5.4 | TRY 1.01T | TRY 7,529.57 | 4.59% down | 66% down | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 6.8 | TRY 4.93T | TRY 47,639.71 | 1.36% down | 36% up | ||
| 26 | Johnson & JohnsonJNJ · Health Care | 7.0 | TRY 33.2T | TRY 13,791.69 | 1.86% down | 38% up | ||
| 27 | Arrowhead PharmaceuticalsARWR · Health Care | 7.4 | TRY 308.1B | TRY 2,179.15 | 0.52% up | 10% up | ||
| 28 | United TherapeuticsUTHR · Health Care | 7.7 | TRY 1.24T | TRY 29,191.96 | 0.89% down | 23% up | ||
| 29 | AbbVieABBV · Health Care | 8.3 | TRY 25.45T | TRY 14,399.82 | 2.48% down | 26% up | ||
| 30 | GenmabGMAB · Health Care | 8.5 | TRY 1.59T | TRY 2,586.34 | 1.29% down | 70% up | ||
| 31 | BeOne MedicinesONC · Health Care | 8.6 | TRY 2.33T | TRY 20,379.56 | 2.20% down | 17% up | ||
| 32 | Corcept TherapeuticsCORT · Health Care | 9.7 | TRY 373.5B | TRY 3,412.94 | 3.41% down | 8% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | 9.7 | TRY 470.5B | TRY 20,255.76 | 4.81% down | 24% down | ||
| 34 | Travere TherapeuticsTVTX · Health Care | 9.9 | TRY 244.5B | TRY 2,546.75 | 1.16% down | 44% up | ||
| 35 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 11.0 | TRY 375.7B | TRY 4,781.87 | 0.29% down | 126% up | ||
| 36 | Axsome TherapeuticsAXSM · Health Care | 11.1 | TRY 356B | TRY 6,767.64 | 1.28% down | 7% down | ||
| 37 | Vertex PharmaceuticalsVRTX · Health Care | 11.4 | TRY 6.87T | TRY 27,105.34 | 0.62% up | 27% up | ||
| 38 | Mirum PharmaceuticalsMIRM · Health Care | 11.5 | TRY 303.3B | TRY 4,646.73 | 0.22% up | 31% up | ||
| 39 | TG TherapeuticsTGTX · Health Care | 16.1 | TRY 500.7B | TRY 3,312.47 | 4.75% up | 107% up | ||
| 40 | Royalty PharmaRPRX · Health Care | 16.8 | TRY 2.01T | TRY 3,496.77 | 0.97% up | 78% up | ||
| 41 | Eli LillyLLY · Health Care | 18.9 | TRY 62.16T | TRY 69,780.89 | 2.24% down | 35% up | ||
| 42 | Ascendis PharmaASND · Health Care | 22.1 | TRY 892.1B | TRY 13,600.83 | 0.54% down | 28% up | ||
| 43 | Ligand PharmaceuticalsLGND · Health Care | 22.3 | TRY 301.9B | TRY 15,090.91 | 1.86% up | 43% up | ||
| 44 | BridgeBio PharmaBBIO · Health Care | 30.1 | TRY 762.7B | TRY 3,915.31 | 1.10% up | 17% up | ||
| 45 | InsmedINSM · Health Care | 43.5 | TRY 1.33T | TRY 6,058.15 | 1.41% down | 40% down | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | 43.9 | TRY 419.9B | TRY 6,056.63 | 3.00% up | 13% up | ||
| 47 | CytokineticsCYTK · Health Care | 81.0 | TRY 359.4B | TRY 2,580.28 | 0.93% down | 20% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | 178 | TRY 412.9B | TRY 6,326.41 | 0.63% up | 46% up | ||
| 49 | Dianthus TherapeuticsDNTH · Health Care | 2367 | TRY 243B | TRY 4,315.94 | 1.60% down | 113% up | ||
| 50 | Roivant SciencesROIV · Health Care | 3370 | TRY 1.4T | TRY 1,937.36 | 0.75% down | 90% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 50.4257 TRY). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies have the lowest P/S ratio?
Grifols (0.7), Viatris (1.7) and GSK (2.2) have the lowest P/S ratio of the 50 pharmaceutical companies ranked here as of 18 Nov 2026, 19:33 UTC.
How many pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 50 pharmaceutical companies ranked by P/S ratio have a combined market value of TRY 255.14T as of 18 Nov 2026, 19:33 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.